Analyst Reco. Adverum Biotechnologies, Inc.

Equities

ADVM

US00773U2078

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-10 pm EDT			5-day change	1st Jan Change
7.5 ^USD	+2.04%		-3.23%	-0.37%

May. 16	Transcript : Adverum Biotechnologies, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:40 PM
May. 09	Adverum Biotechnologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Starts Adverum Biotechnologies With Buy Rating, $30 Price Target	Apr. 30	MT
Mizuho Adjusts Price Target on Adverum Biotechnologies to $22 From $40 After Model Update, Maintains Buy Rating	Apr. 29	MT
RBC Cuts Price Target on Adverum Biotechnologies to $2 From $3, Keeps Sector Perform, Speculative Risk	Mar. 19	MT
Mizuho Starts Adverum Biotechnologies With Buy Rating, Price Target is $2	Nov. 02	MT
Chardan Upgrades Adverum Biotechnologies to Buy From Neutral, Expecting Positive Outcome From Ongoing LUNA Trial, Raises Price Target to $4 From $2	23-08-11	MT
Ladenburg Thalmann Starts Adverum Biotechnologies at Buy With $2 Price Target	23-03-07	MT
RBC Cuts Price Target on Adverum Biotechnologies to $3 From $5, Maintains Sector Perform, Speculative Risk	22-11-11	MT
Chardan Trims Price Target on Adverum Biotechnologies to $2 From $2.50, Retains Neutral Rating	22-11-11	MT
Chardan Research Trims Adverum Biotechnologies' Price Target to $2.50 From $3, Maintains Neutral Rating	22-08-12	MT
Truist Securities Upgrades Adverum Biotechnologies to Buy From Hold, Adjusts Price Target to $4 From $3	22-07-07	MT
CORRECTION : --Goldman Sachs Downgrades Advantage Solutions to Neutral From Buy; Price Target is $7	22-03-04	MT
ADVERUM BIOTECHNOLOGIES : Goldman Sachs Downgrades Adverum Biotechnologies to Neutral From Buy, Adjusts PT to $3 From $10	21-07-23	MT
ADVERUM BIOTECHNOLOGIES : Chardan Adjusts Price Target on Adverum Biotechnologies to $3 From $5 After Eye Drug Cancellation, Maintains Neutral Rating	21-07-23	MT
ADVERUM BIOTECHNOLOGIES : SVB Leerink Adjusts Adverum Biotechnologies' Price Target to $2 from $5, Keeps Market Perform Rating	21-07-23	MT
ADVERUM BIOTECHNOLOGIES : Cantor Fitzgerald Downgrades Adverum Biotechnologies to Neutral From Overweight, Adjusts Price Target to $3 From $23	21-07-23	MT
ADVERUM BIOTECHNOLOGIES : SVB Leerink Downgrades Adverum Biotechnologies to Market Perform From Outperform; Price Target is $5	21-05-03	MT
ADVERUM BIOTECHNOLOGIES : Goldman Sachs Adjusts Price Target for Adverum Biotechnologies to $10 From $28, Maintains Buy Rating	21-04-29	MT
ADVERUM BIOTECHNOLOGIES : Truist Securities Downgrades Adverum Biotechnologies to Hold From Buy, Adjusts PT to $9 From $30	21-04-29	MT
ADVERUM BIOTECHNOLOGIES : Chardan Downgrades Adverum Biotechnologies to Neutral Rating From Buy on Eye Drug Side Effects, Adjusts Price Target to $5 From $20	21-04-29	MT
ADVERUM BIOTECHNOLOGIES : RBC Capital Downgrades Adverum Biotechnologies to Sector Perform Rating From Outperform, Lowers PT to $6 From $30	21-04-29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Adverum Biotechnologies, Inc.

Equities

ADVM

US00773U2078

Analyst Reco.

Filters